Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Mivebresib + Venetoclax|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Mivebresib||ABBV-075||BET Inhibitor (Pan) 27||Mivebresib (ABBV-075) is a bromodomain (BET) inhibitor, which may disrupt transcriptional regulation and lead to apaotosis of tumor cells (PMID: 28416490, PMID: 31420359).|
|Venetoclax||Venclexta||ABT-199|RG7601|GDC-0199|ABT119||BCL2 inhibitor 17||Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||Mivebresib + Venetoclax||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Mivebresib (ABBV-075) and Venclexta (venetoclax) worked synergistically to decrease viability of a acute myeloid leukemia (AML) cell lines in culture, and the combination resulted in increased tumor growth inhibition in an AML cell line xenograft model compared to either agent alone (PMID: 28416490).||28416490|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|